Children's Brain Tumor Network Welcomes Dr. John Prensner
The Children's Brain Tumor Network (CBTN) has announced a significant leadership change with the appointment of Dr. John Prensner as its new Scientific Co-Chair. A dedicated pediatric neuro-oncologist and physician-scientist, Dr. Prensner operates at the Chad Carr Pediatric Brain Tumor Center at the University of Michigan. His dual focus on clinical care and groundbreaking research in genomics and RNA biology positions him as a vital asset in the battle against high-risk brain tumors in children.
Dr. Prensner's Vision and Role
In his new role as Co-Chair, Dr. Prensner is poised to influence CBTN's overall scientific strategy significantly. One of his primary objectives will be to enhance partnerships among multiple institutions, fostering collaboration that drives forward-thinking research initiatives. Additionally, he is passionate about championing open data initiatives, which are essential to fast-tracking the translation of research discoveries into practical treatments for young patients.
Transforming Pediatric Cancer Research
Dr. Prensner expressed his enthusiasm for the opportunity, stating, "CBTN demonstrates how open science can transform the pace of pediatric cancer research. By uniting data, tools, and expertise across institutions, we are establishing a foundation for tomorrow's breakthroughs in medical care." This approach encourages researchers to harness the power of shared information to rapidly implement innovative methods that could save lives.
Research Focus and Contributions
Leading The Prensner Lab, Dr. Prensner's research delves into the complexities of the non-coding genome—the vast majority of DNA that does not code for known genes—and investigates how RNA translation and the dark proteome contribute to the development of childhood brain tumors, including medulloblastoma, ATRT, and DIPG/DMG. His work is critical in uncovering potential cancer-driving genes and identifying novel RNA-based therapeutic approaches that could alter the treatment landscape for these aggressive tumors.
A Collaborative Leader
Dr. Prensner is recognized as a leader in international collaboration within the field of pediatric neuro-oncology. He co-chairs the global TransCODE Consortium focused on non-canonical proteomics, reinforcing efforts to standardize data and enhance research into pediatric gliomas. His involvement with both CBTN and the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC) illustrates his commitment to fostering global research networks that can expedite scientific progress.
Commitment to Patient Care
Adam Resnick, Executive Chair of CBTN, praised Dr. Prensner's holistic approach, noting, "Dr. John Prensner is a collaborative physician-scientist whose leadership unites cutting-edge RNA biology with compassionate clinical care to accelerate therapies for children with brain tumors." This synergy between advanced scientific research and genuine patient care is crucial for producing real-world results that benefit children and families grappling with brain tumors.
About the Children's Brain Tumor Network
The Children's Brain Tumor Network is a pioneering global research initiative devoted to reshaping pediatric brain tumor research and enhancing treatment options. With a diverse network of 35 member institutions, CBTN boasts an impressive repository of more than 110,000 biospecimens and has enrolled over 8,000 participants, creating the largest pediatric brain tumor data resource globally. By promoting real-time data sharing and fostering interdisciplinary collaboration, CBTN empowers researchers to drive forward innovations that provide timely answers to families in need.
Frequently Asked Questions
Who is Dr. John Prensner?
Dr. John Prensner is a pediatric neuro-oncologist and physician-scientist appointed as the Scientific Co-Chair of the Children's Brain Tumor Network.
What is the role of the Children's Brain Tumor Network?
The CBTN aims to transform pediatric brain tumor research and care by leveraging global collaboration and promoting open data initiatives.
What are the primary research interests of Dr. Prensner?
Dr. Prensner's research focuses on the non-coding genome and RNA biology in relation to childhood brain tumors, including identifying new cancer driver genes.
How does collaboration contribute to pediatric cancer research?
Collaboration enables the sharing of data and resources across institutions, accelerating the translation of research into effective treatments for patients.
What impact does the CBTN have on families?
By fostering research and innovation, the CBTN provides families with faster access to breakthroughs in treatment strategies for pediatric brain tumors.
